CoChat

Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease

Van Raamsdonk, Jeremy M., Pearson, Jacqueline, Bailey, Craig D. C., Rogers, Daniel A., Johnson, Gail V. W., Hayden, Michael R., Leavitt, Blair R. · 2005 · Journal of Neurochemistry
Cited by 107

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Huntington disease (HD) is an adult onset neurodegenerative disorder characterized by selective atrophy and cell loss within the striatum. There is currently no treatment that can prevent the striatal neuropathology. Transglutaminase (TG) activity is increased in HD patients, is associated with cell death, and has been suggested to contribute to striatal neuronal loss in HD. This work assesses the therapeutic potential of cystamine, an inhibitor of TG activity with additional potentially beneficial effects. Specifically, we examine the effect of cystamine on striatal neuronal loss in the YAC128 mouse model of HD. We demonstrate here for the first time that YAC128 mice show a forebrain‐specific increase in TG activity compared with wild‐type (WT) littermates which is decreased by oral delivery of cystamine. Treatment of symptomatic YAC128 mice with cystamine starting at 7 months prevented striatal neuronal loss. Cystamine treatment also ameliorated the striatal volume loss and striatal neuronal atrophy observed in these animals, but was unable to prevent motor dysfunction or the down‐regulation of dopamine and cyclic adenosine monophsophate‐regulated phosphoprotein (DARPP‐32) expression in the striatum. While the exact mechanism responsible for the beneficial effects of cystamine in YAC128 mice is uncertain, our findings suggest that cystamine is neuroprotective and may be beneficial in the treatment of HD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1471-4159.2005.03357.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 107

Metadata

Authors
Van Raamsdonk, J. M., Pearson, J., Bailey, C. D. C., Rogers, D. A., Johnson, G. V. W., Hayden, M. R., & Leavitt, B. R.
Venue
Journal of Neurochemistry
Publisher
Wiley
Published
2005-08-25
Volume
95
Issue
1
Pages
210-220
ISSN
  • 0022-3042 (ISSN-L)
  • 1471-4159
OpenAlex
W1515840075
Cited by
107
References
1
FWCI
2.72
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. https://app.cochat.ai/papers/10.1111/j.1471-4159.2005.03357.x
The paper
Van Raamsdonk, J. M., Pearson, J., Bailey, C. D. C., Rogers, D. A., Johnson, G. V. W., Hayden, M. R., & Leavitt, B. R. (2005). Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. Journal of Neurochemistry. https://doi.org/10.1111/j.1471-4159.2005.03357.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.